You are here
IRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped
Important Commercial Milestone Demonstrates Growing Worldwide Awareness of MicroPulse Technology for Treatment of Glaucoma
MOUNTAIN VIEW, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser System, which utilizes the Company’s proprietary MicroPulse® technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefecture, was the recipient of the 1,000th system.
“MicroPulse Laser therapy is a new and very promising technology in Japan, providing an effective and non-incisional treatment for glaucoma patients with a range of stages of the disease. The earlier clinical research performed in US, Europe and Asia showed that MicroPulse is safe and effective in IOP reduction and medication use decrease, and my clinical findings confirm the previous studies’ results. As one of the first sites in Japan to use the Cyclo G6 for glaucoma treatment, we have seen significant benefits. Even patients with previous intraocular surgeries experienced positive results,” said Makoto Aihara MD, PhD, Professor and Chair, University of Tokyo.
The Cyclo G6 system is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the Cyclo G6 because it is safe, minimally invasive, non-incisional, repeatable and durable. Moreover, the Cyclo G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care – from early to late stage glaucoma. More than 80,000 patients worldwide have been treated with the Cyclo G6 system.
“In my opinion, MicroPulse Laser therapy shifts the paradigm of glaucoma treatments in Japan. It provides a new choice for a safe, effective, and non-incisional treatment on various glaucoma patients with mild, moderate, and late stage disease. The MicroPulse procedure can be performed on a wide variety of patients not responding to medications or not qualified for incisional surgeries. Recent industry meetings and clinical presentations of leading physicians using the MicroPulse procedure in the United States, Europe and Asia have demonstrated and proven that fact. My initial clinical experience with it confirms these findings,” commented Dr. Ryo Taniguchi.
“We are delighted to achieve this exciting milestone in the commercialization of our Cyclo G6 laser system, as it not only demonstrates the traction the platform is gaining worldwide, but highlights the progress we have made in transforming our business to delivering a compelling and proven treatment alternative for patients suffering from glaucoma,” said William Moore, Chief Executive Officer of IRIDEX.
IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning future sales of Company products and industry trends. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals, market adoption of its products and industry developments. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Pascale Communications, LLC.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo